CHUM to lead prostate cancer biomarker effort
MONTREAL, Quebec—Researchers at the University of Montreal's Hospital Center (also known as Centre Hospitalier de l'Université de Montréal, or CHUM) will lead a pan-Canadian study to discover biomarkers for prostate cancer treatment. The four-year study is funded by $3.5 million from the Terry Fox Foundation and $556,000 from the Canadian Partnership Against Cancer. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network will seek new ways to determine which forms of prostate cancer call for immediate treatment and which do not, and to predict which patients are at risk for cancer progression following surgery or radiation therapy.
"Bringing together expertise and resources from across the country through this network will help to advance the science needed to improve the lives of Canadian men diagnosed with prostate cancer," said Robin Harkness, a Canadian Partnership Against Cancer research specialist and executive director of the Canadian Cancer Research Alliance.